Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.00% is 100% below its 5-year average of 1.26%, near the low end of its 5-year range (0.00%–28.34%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
DEBT TO ASSETS RATIO
0.00%
DEBT TO ASSETS RATIO AVG TTM
0.00%
DEBT TO ASSETS RATIO AVG 3Y
0.13%
DEBT TO ASSETS RATIO AVG 5Y
1.26%
DEBT TO ASSETS RATIO AVG 10Y
7.44%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
-100.00%
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
-100.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Pulmatrix, Inc.
Market Cap
$5.24M
Debt to Assets Ratio
0.00%
TTM Avg
0.00%
3Y Avg
0.13%
5Y Avg
1.26%
Market Cap
$5.21M
Debt to Assets Ratio
0.25%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.27M
Debt to Assets Ratio
0.15%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.12M
Debt to Assets Ratio
0.42%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.03M
Debt to Assets Ratio
0.49%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pulmatrix, Inc. (PULM) | $5.24M | 0.00% | 0.00% | 0.13% | 1.26% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.21M | 0.25% | N/A | N/A | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.20M | 0.00% | N/A | N/A | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.27M | 0.15% | N/A | N/A | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.19M | 0.14% | N/A | N/A | N/A |
| Soligenix, Inc. (SNGX)vs › | $5.34M | 0.03% | N/A | N/A | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.12M | 0.42% | N/A | N/A | N/A |
| Imunon, Inc. (IMNN)vs › | $5.03M | 0.52% | N/A | N/A | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.03M | 0.49% | N/A | N/A | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.95M | 0.02% | N/A | N/A | N/A |
Debt/Assets
0.0%
Debt/Equity
0.00
Current Ratio
4.70
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.15% |
| 2024-03-31 | 28.34% |
| 2023-12-31 | 25.78% |
| 2023-09-30 | 23.45% |
| 2023-06-30 | 1.14% |
| 2023-03-31 | 2.16% |
| 2022-12-31 | 2.09% |
| 2022-09-30 | 2.76% |
| 2022-06-30 | 3.45% |
| 2022-03-31 | 3.68% |
| 2021-12-31 | 3.89% |
| 2021-09-30 | 1.61% |
| 2021-06-30 | 1.81% |
| 2021-03-31 | 2.10% |
| 2020-12-31 | 4.57% |
| 2020-09-30 | 4.41% |
| 2020-06-30 | 5.83% |
| 2020-03-31 | 1.66% |
| 2019-12-31 | 1.87% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 18.39% |
| 2017-12-31 | 20.16% |
| 2017-09-30 | 20.16% |
| 2017-06-30 | 19.34% |
| 2017-03-31 | 22.74% |
| 2016-12-31 | 34.83% |
| 2016-09-30 | 25.13% |
| 2016-06-30 | 23.53% |
| 2016-03-31 | 16.78% |
| 2015-12-31 | 14.98% |
| 2015-09-30 | 14.11% |
| 2015-06-30 | 13.33% |
| 2015-03-31 | 400.51% |
| 2014-12-31 | 334.37% |
| 2014-09-30 | 0.02% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
| 2013-12-31 | 0.00% |
| 2013-09-30 | 0.00% |
| 2013-06-30 | 0.00% |
| 2013-03-31 | 0.00% |
